As Esperion Therapeutics INC (ESPR) Stock Rose, Sabby Management LLC Boosted Its Holding

Investors sentiment decreased to 0.95 in Q2 2018. Its down 0.55, from 1.5 in 2018Q1. It worsened, as 43 investors sold ESPR shares while 35 reduced holdings. 18 funds opened positions while 56 raised stakes. 26.84 million shares or 9.29% more from 24.56 million shares in 2018Q1 were reported. The Illinois-based Grp One Trading LP has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Public Employees Retirement Sys Of Ohio holds 24,064 shares. Parkside Retail Bank And has invested 0.01% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Tiverton Asset Ltd Liability Corporation holds 0.01% or 3,587 shares. C Group Incorporated Hldg A S has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 4,304 shares. Hamilton Lane Advisors Limited Liability Company accumulated 21,562 shares or 0.91% of the stock. Jasper Ridge Prns Limited Partnership invested 0.03% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 1,168 shares. Ameritas Investment Prtn accumulated 1,993 shares. 17,403 are held by Manufacturers Life Ins The. J Goldman Lp has invested 0.19% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Dimensional Fund LP reported 15,919 shares. Aqr Capital Ltd Limited Liability Company accumulated 0% or 11,442 shares. Jpmorgan Chase And has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 68,747 shares. Keybank Association Oh has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Sabby Management Llc increased its stake in Esperion Therapeutics Inc (ESPR) by 690.01% based on its latest 2018Q2 regulatory filing with the SEC. Sabby Management Llc bought 129,881 shares as the company’s stock rose 15.64% with the market. The hedge fund held 148,704 shares of the health care company at the end of 2018Q2, valued at $5.83M, up from 18,823 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Esperion Therapeutics Inc for a number of months, seems to be bullish on the $1.38B market cap company. The stock decreased 4.84% or $2.62 during the last trading session, reaching $51.49. About 428,138 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has declined 8.71% since December 8, 2017 and is downtrending. It has underperformed by 24.33% the S&P500.

Sabby Management Llc, which manages about $835.79 million and $647.22M US Long portfolio, decreased its stake in Biogen Inc (NASDAQ:BIIB) by 30,796 shares to 152,102 shares, valued at $44.15 million in 2018Q2, according to the filing. It also reduced its holding in Astrazeneca Plc (Put) by 5,015 shares in the quarter, leaving it with 3,365 shares, and cut its stake in Spdr S&P 500 (Put).

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: which released: “Eserion down 14% premarket on lower Praluent pricing – Seeking Alpha” on March 12, 2018, also with their article: “ESPR To Submit NDAs In Q1, GRFS’ Alzheimer’s Study Brings Hope, RTRX On Watch – Nasdaq” published on October 28, 2018, published: “Esperion announces positive results from phase 3 bempedoic acid / ezetimibe combination pill study – Seeking Alpha” on August 27, 2018. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: and their article: “Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018 – GlobeNewswire” published on November 10, 2018 as well as‘s news article titled: “Esperion up 8% premarket – Seeking Alpha” with publication date: October 26, 2018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 3 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Esperion Therapeutics had 3 analyst reports since July 11, 2018 according to SRatingsIntel. The rating was downgraded by Northland Capital on Wednesday, July 11 to “Market Perform”. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Friday, August 17 by Citigroup.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.